1. Immune Checkpoint Inhibitors in Lung Cancer

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. Data that we discuss should be considered preliminary until published in a peer-reviewed journal.

4. Checkpoint Inhibitors Approved for Use in Second-Line Therapy

5. Checkpoint Inhibitors Approved for Other Uses

6. KEYNOTE-024

7. KEYNOTE-189

8. KEYNOTE-189 (cont)

9. KEYNOTE-042

10. IMpower150

11. IMpower150 Subgroups

12. CheckMate 227

13. CheckMate 227 Subgroups

14. KEYNOTE-407

15. KEYNOTE-407 Subgroups

16. IMpower131

17. Faculty Comments on Front-Line Trials

18. Patients Taking Baseline Steroids

19. PACIFIC

20. Other Trials of Interest From ASCO® 2018

21. Concluding Remarks

22. Abbreviations

23. Abbreviations (cont)